Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Available (expanded access)

Conditions studied: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma

In brief

This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.

Key facts

Study ID

NCT07573215

Run by

Revolution Medicines, Inc.

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years old and has provided informed consent.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Histologically or cytologically confirmed PDAC with metastatic disease.
• Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.
• At least one prior line of systemic therapy in the metastatic setting, which must include either a fluoropyrimidine-based or gemcitabine-based regimen.
• Received and progressed, been intolerant to prior standard therapy, or no longer expected to benefit from standard therapies.
• Adequate bone marrow, renal, hepatic, and coagulation functions.
• Ineligible for, or unable to enroll in, another clinical trial of daraxonrasib, if available.
• Able to take oral medications

You may not qualify if…

• History of known central nervous system metastatic disease.
• Concurrent systemic anticancer therapy.
• Significant cardiovascular disease.
• Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).
• Active uncontrolled systemic infection.
• Major surgery within 28 days before enrollment.
• Additional inclusion and exclusion criteria may apply.

Where it is running

• Southern Cancer Center — Mobile, Alabama, United States
• Alaska Oncology and Hematology — Anchorage, Alaska, United States
• Cancer and Blood Specialists of Arizona — Casa Grande, Arizona, United States
• Mayo Clinic - Arizona — Phoenix, Arizona, United States
• Honor Health — Scottsdale, Arizona, United States
• University of Arizona Cancer Center — Tucson, Arizona, United States
• Mercy Hospital Fort Smith — Fort Smith, Arkansas, United States
• Genesis Cancer and Blood Institute — Hot Springs, Arkansas, United States
• Care Oncology Center — Chula Vista, California, United States
• City of Hope Cancer Center (California) — Duarte, California, United States
• Cancer and Blood Specialty Clinics — Fountain Valley, California, United States
• California Cancer Associates for Research and Excellence — Fresno, California, United States
• USC Norris Comprehensive Cancer Hospital — Los Angeles, California, United States
• Cedars-Sinai Medical Center — Los Angeles, California, United States
• UCLA Health Westlake Village — Los Angeles, California, United States
• University of California — Los Angeles, California, United States
• El Camino Health — Mountain View, California, United States
• University of California - San Francisco — Oakland, California, United States
• UCI Health — Orange, California, United States
• Desert Care Network Comprehensive Cancer — Palm Springs, California, United States
• The Kaiser Permanente Medical Group — Roseville, California, United States
• Sutter Health — Sacramento, California, United States
• Sutter Health — San Francisco, California, United States
• CommonSpirit — San Luis Obispo, California, United States
• Southern Cancer Center — Daphne, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.